Transcatheter Aortic Valve Replacement Clinical Trial
A sample of plasma and whole blood will be obtained at 4 time points (pre-procedural, early post-procedural, at hospital discharge and during an eventual visite at 3 or 6 months post-procedural). Test for platelet reactivity (LTA, light transmittance aggregometry and Elisa PRI, Platelet reactivity index), multimeric VWF (von Willebrand factor) and blood level of NET: neutrophil extracellular traps(flow cytometry and ELISA) analyses will be performed at the time of blood sampling. Aliquots of plasma will be stored and frozen for further analyses
There are two major objectives:
- To correlate changes in VWF, platelet reactivity and blood level of NET after TAVR with
clinical outcomes
- To correlate changes in VWF, platelet reactivity and blood level of NET with
antithrombotic regimens after TAVR (direct anticoagulants apixaban versus standard of
care, ie Vitamin K antagonist or antiplatelet therapy).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05465655 -
Cara CDRM (Conduction Disturbance Risk Monitor) 2.0
|
N/A | |
Recruiting |
NCT04870424 -
Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
|
Phase 3 | |
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Recruiting |
NCT05758701 -
CT TAVR Abdomen Study
|
Phase 4 | |
Active, not recruiting |
NCT04281771 -
Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI
|
N/A | |
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Recruiting |
NCT05235555 -
EffecTAVI Registry
|
||
Completed |
NCT05082337 -
The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures
|
N/A | |
Completed |
NCT01627691 -
REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System
|
N/A | |
Recruiting |
NCT05075590 -
Coronary Access After Supra-Annular THV Implantation
|
N/A | |
Completed |
NCT01651780 -
Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH
|
Phase 3 | |
Recruiting |
NCT05259241 -
ADAPT Transcatheter Aortic Valve Intervention (TAVI & Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI)
|
N/A | |
Completed |
NCT04489914 -
Observational Study on the Application of High-Flow Therapy After Percutaneous Transfemoral Aortic Valve Replacement
|
||
Recruiting |
NCT03649594 -
Risk Stratification Post TAVI Using TEG
|
||
Completed |
NCT04659538 -
The CAPTIS® Study - Embolic Protection in TAVR
|
N/A | |
Recruiting |
NCT04107038 -
Monitored Anesthesia Care vs. General Anesthesia for Transcatheter Aortic Valve Replacement
|
N/A | |
Withdrawn |
NCT04268160 -
GPx Activity in Subjects With Aortic Stenosis Undergoing TAVR
|
||
Recruiting |
NCT05217888 -
The Sentinel Registry
|
||
Recruiting |
NCT04982406 -
Transcatheter Aortic Valve Replacement (TAVR) Effects on Cardiac Conduction System
|